FDA Issues Warning For BMS Hepatitis B Drug Entecavir

Armen Hareyan's picture

BMS Hepatitis B Drug Entecavir


FDA on Thursday issued a warning that Bristol-Myers Squibb'shepatitis B drug entecavir might increase the likelihood of developingresistance to antiretroviral drugs among people coinfected with HIV, Reutersreports. The agency also added a black box warning to the drug's label.BMS -- which manufactures and sells entecavir under the brand nameBaraclude -- in a letter to physicians wrote that people coinfectedwith hepatitis B and HIV should not take entecavir unless they aretaking standard antiretrovirals. According to the warning, drugresistance can develop if a person is not being treated for HIV.

Thewarning also said that HIV testing should be offered to any person whoconsiders taking entecavir (Reuters, 8/16). There are morethan four million people worldwide living with both hepatitis B and HIVwho need treatment for hepatitis B but have not started antiretrovirals(Kaiser Daily HIV/AIDS Report, 3/2)

Reprinted with permission from kaisernetwork.org. You can view theentire Kaiser DailyHIV/AIDS Report, search the archives, and sign up for email delivery at kaisernetwork.org/email . TheKaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service ofThe Henry J. Kaiser Family Foundation.

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.